Turning Point Therapeutics

Turning Point Therapeutics

World Rank (Jan-05-2024)
3,662
World Rank (Jul-30-2023)
3,662
Market Cap (Jul-30-2023)
3.810 Billion USD
World Rank (Jan-07-2022)
6,033
Market Cap (Jan-07-2022)
2.125 Billion USD
World Rank (Jan-01-2021)
2,605
Market Cap (Jan-01-2021)
5.870 Billion USD
Headquarters Country
USA
Employee Count
250
Employee Count as of Date
As on 2021
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
30 Million USD
Annual Net Income in USD
-236 Million USD
Annual Results for Period Ending
Dec-2021 ending year
Total Assets in USD
1,003 Million USD
Total Liabilities in USD
49 Million USD
Total Equity in USD
954 Million USD
Balance Sheet for Period Ending
Dec-2021 ending year
Business Sector
Healthcare
Biotechnology
Company Website
TURNING POINT THERAPEUTICS
Company Profile

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Headquarters is in USA.

Turning Point develops kinase inhibitors, a class of targeted cancer drugs, that are designed to bind to cancer cells with greater precision and affinity than existing therapies.

Bristol Myers Squibb has acquired Turning Point Therapeutics for 4.1 billion USD in an all-cash transaction and completed the transaction in 2022.

Founded Year
2013
Company SubCategory
Top Healthcare Companies in USA

Share